Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Omeros Corporation (OMER)
USD10.45
-0.05 (-0.48%)
US NASDAQ Healthcare Biotechnology
Address
The Omeros Building 98119
Seattle, WA, US
Seattle, WA, US
CEO
Gregory A. Demopulos
Website
omeros.com
IPO
2009-10-08
CIK 1285819 ISIN US6821431029
Description
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
News Sentiment (7d)
5 articles
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PRNewsWire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER GlobeNewsWire
- Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? The Motley Fool
- OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm Business Wire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD10.45
-0.05 (-0.48%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.55
Float Shares
69.23M
Free Float %
96.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.79% | -0.67% | +28.46% | +29.02% | +114.22% | -14.09% | +288.42% | +158.49% | -17.31% | +48.49% | +69.07% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (19 ratings, all time)
Buy
Price Targets & DCF
Current price
10.45
Low
40.00
+282.8%
Consensus
40.00
+282.8%
Median
40.00
+282.8%
High
40.00
+282.8%
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
23.00
+120.1%
|
| All Time | 4 |
17.75
+69.9%
|
Quality scores
Altman Z-Score
-3.18
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+98.1% ★ Q1'26: +206.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.2% Q1'26: +55.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.96× Q1'26: -0.17× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.51M
est: 11.49M (+17.6%)
|
41.62M
est: 41.01M (+1.5%)
|
64.83M
est: 71.35M (-9.1%)
|
29.87M
est: 23.68M (+26.1%)
|
111.81M
est: 110.18M (+1.5%)
|
—
est: 78.09M (-100.0%)
|
—
est: 146.83M (-100.0%)
|
—
est: 65.19M (-100.0%)
|
—
est: 73.03M (-100.0%)
|
—
est: 6.00M (-100.0%)
|
—
est: 2.53M (-100.0%)
|
77.09M
42.88M – 154.25M
+2,953.0% YoY
|
252.16M
140.27M – 504.58M
+227.1% YoY
|
448.73M
249.62M – 897.92M
+78.0% YoY
|
654.62M
364.14M – 1.31B
+45.9% YoY
|
799.02M
444.47M – 1.60B
+22.1% YoY
|
| EBITDA |
-71.31M
|
-58.63M
|
-41.90M
|
-122.47M
|
-60.04M
|
-168.02M
|
-170.49M
|
-158.38M
|
-143.16M
|
-157.00M
|
-121.83M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-71.52M
|
-58.93M
|
-42.45M
|
-123.43M
|
-61.83M
|
-169.64M
|
-171.88M
|
-159.33M
|
-144.08M
|
-157.95M
|
-122.80M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-75.10M
est: -121.58M (+38.2%)
|
-66.75M
est: -101.12M (+34.0%)
|
-53.48M
est: -57.59M (+7.1%)
|
-126.76M
est: -166.81M (+24.0%)
|
-84.49M
est: -88.42M (+4.4%)
|
-138.06M
est: -149.50M (+7.7%)
|
-111.41M
est: -64.56M (-72.6%)
|
47.42M
est: -114.02M (+141.6%)
|
-117.81M
|
-156.82M
est: -253.71M (+38.2%)
|
-3.35M
est: -175.84M (+98.1%)
|
-68.59M
-115.87M – -21.31M
+61.0% YoY
|
64.84M
20.14M – 109.54M
+194.5% YoY
|
162.11M
149.10M – 175.12M
+150.0% YoY
|
248.32M
105.08M – 571.47M
+53.2% YoY
|
317.39M
134.30M – 730.42M
+27.8% YoY
|
| SGA |
35.33M
|
43.78M
|
52.04M
|
51.72M
|
62.84M
|
47.69M
|
53.46M
|
50.67M
|
49.66M
|
49.74M
|
41.50M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.00
est: -2.09 (+4.3%)
|
-1.65
est: -1.74 (+5.1%)
|
-1.17
est: -0.99 (-18.2%)
|
-2.61
est: -2.87 (+9.0%)
|
-2.16
est: -1.52 (-42.1%)
|
-2.41
est: -2.57 (+6.2%)
|
3.12
est: -1.11 (+381.1%)
|
0.46
est: -1.96 (+123.5%)
|
-1.88
|
-2.70
est: -2.93 (+7.9%)
|
-0.05
est: -2.03 (+97.4%)
|
-0.79
-1.82 – -0.34
+61.0% YoY
|
0.75
0.32 – 1.72
+194.5% YoY
|
2.55
2.35 – 2.76
+240.6% YoY
|
3.91
1.65 – 9.00
+53.2% YoY
|
5.00
2.11 – 11.50
+27.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-21 | D. Boral Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-116.09M
OE per share TTM
-1.90
Owner's Yield
-12.38%
Maintenance CapEx ratio
0.00%
Maint CapEx / Avg PPE
146.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
33
Total invested
9.99M
Insider transactions (90d)
0
Beneficial owners (>5%)
16
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 8.4%2 | 42.40M | 8.40% | 42.40M | — | 42.40M | — | IN | United States | 2018-02-14 | ↗ |
| 2 | Gregory A. Demopulos, M.D. | 5.00M | 8.75% | 5.00M | — | 5.00M | 5.00M | IN | United States | 2020-02-14 | ↗ |
| 3 | 8.96% † | 4.62M | 8.96% | 4.62M | — | 4.62M | — | IN | United States | 2019-02-13 | ↗ |
| 4 | 13-5156620 | 4.46M | 7.10% | — | — | — | 4.46M | BD, IA | NEW YORK STATE | 2022-02-04 | ↗ |
| 5 | (1) BlackRock, Inc. | 4.28M | 6.80% | 4.22M | — | 4.28M | — | HC | Delaware | 2024-01-29 | ↗ |
| 6 | The Vanguard Group - 23-1945930 | 3.36M | 5.37% | — | 114.0K | 3.20M | 158.3K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 7 | David E. Shaw | 2.46M | 5.00% | — | 2.44M | — | — | IN | United States | 2019-05-10 | ↗ |
| 8 | Cormorant Asset Management, LLC | 900.0K | 1.87% | — | 900.0K | — | — | OO | Delaware | 2018-02-14 | ↗ |
| 9 | Bihua Chen | — | 0.00% | — | — | — | — | IN | United States | 2022-02-14 | ↗ |
| 10 | Consonance Capital Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 11 | Consonance Capital Opportunity Fund Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 12 | Consonance Capman GP LLC | — | 0.00% | — | — | — | — | HC, OO | Delaware USA | 2021-02-17 | ↗ |
| 13 | Cormorant Asset Management, LP | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 14 | Cormorant Global Healthcare GP, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 15 | Cormorant Global Healthcare Master Fund, LP | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2022-02-14 | ↗ |
| 16 | Mitchell Blutt | — | 0.00% | — | — | — | — | HC, IN | USA | 2021-02-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
33
-145 vs prev Q
New positions
4
Closed positions
127
Increased
18
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 150.0K +150.0K (+100.0%) | 2.58B +2.6B (+100.0%) | 0.23% +0.226 pp | 2.15% +2.149 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 5.06M +610.3K (+13.7%) | 86.95M +68.7M (+376.3%) | 7.64% +0.040 pp | 0.00% +0.001 pp | USD5.71 +200.9% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 4.01M +666.4K (+19.9%) | 68.93M +55.2M (+402.3%) | 6.06% +0.344 pp | 0.00% +0.001 pp | USD12.44 +38.1% | 63 qtrs — |
| 4 | INGALLS & SNYDER LLC | 3.45M -657.9K (-16.0%) | 59.23M +42.4M (+251.8%) | 5.20% -1.805 pp | 2.18% +1.624 pp | USD9.51 +80.7% | 39 qtrs — |
| 5 | UBS GROUP AG | 2.22M +1.5M (+213.5%) | 38.18M +35.3M (+1,213.3%) | 3.35% +2.144 pp | 0.01% +0.006 pp | USD14.64 +17.3% | 45 qtrs — |
| 6 | STIFEL FINANCIAL CORP | 1.81M -2.5K (-0.1%) | 31.08M +23.7M (+318.3%) | 2.73% -0.362 pp | 0.03% +0.021 pp | USD8.97 +91.5% | 46 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.63M +96.0K (+6.3%) | 28.03M +21.7M (+345.1%) | 2.46% -0.159 pp | 0.00% +0.001 pp | USD8.90 +93.0% | 65 qtrs — |
| 8 | STATE STREET CORP | 1.57M +333.8K (+26.9%) | 27.03M +21.9M (+431.7%) | 2.37% +0.259 pp | 0.00% +0.001 pp | USD8.88 +93.5% | 51 qtrs — |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.16M +604.1K (+108.7%) | 19.92M +17.6M (+774.7%) | 1.75% +0.802 pp | 0.00% +0.002 pp | USD11.35 +51.4% | 51 qtrs — |
| 10 | IKARIAN CAPITAL, LLC | 950.0K +950.0K (+100.0%) | 16.32M +16.3M (+100.0%) | 1.43% +1.434 pp | 1.27% +1.274 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 11 | D. E. SHAW & CO., INC. | 755.0K -250.2K (-24.9%) | 12.97M +8.8M (+214.6%) | 1.14% -0.577 pp | 0.01% +0.005 pp | USD9.99 +72.0% | 34 qtrs — |
| 12 | CI PRIVATE WEALTH, LLC | 688.0K +79.3K (+13.0%) | 11.82M +9.3M (+373.4%) | 1.04% -0.001 pp | 0.02% +0.012 pp | USD4.58 +275.1% | 13 qtrs — |
| 13 | NOMURA HOLDINGS INC | 655.0K +611.3K (+1,399.6%) | 11.25M +11.1M (+6,181.7%) | 0.99% +0.914 pp | 0.02% +0.015 pp | USD16.60 +3.5% | 22 qtrs — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 593.2K +39.8K (+7.2%) | 10.19M +7.9M (+349.0%) | 0.90% -0.050 pp | 0.00% +0.001 pp | USD8.65 +98.6% | 55 qtrs — |
| 15 | NORTHERN TRUST CORP | 526.7K -9.0K (-1.7%) | 9.05M +6.9M (+311.9%) | 0.79% -0.120 pp | 0.00% +0.001 pp | USD6.88 +149.7% | 51 qtrs — |
| 16 | TWO SIGMA INVESTMENTS, LP | 524.8K -408.6K (-43.8%) | 9.01M +5.2M (+135.5%) | 0.79% -0.801 pp | 0.01% +0.007 pp | USD3.45 +398.0% | 20 qtrs — |
| 17 | ROYAL BANK OF CANADA | 498.4K -45.3K (-8.3%) | 8.56M +6.3M (+284.0%) | 0.75% -0.176 pp | 0.00% +0.001 pp | USD5.72 +200.3% | 44 qtrs — |
| 18 | CAPTION MANAGEMENT, LLC | 475.7K +475.7K (+100.0%) | 8.17M +8.2M (+100.0%) | 0.72% +0.718 pp | 0.06% +0.056 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 19 | MILLENNIUM MANAGEMENT LLC | 441.8K +40.0K (+10.0%) | 7.59M +5.9M (+360.6%) | 0.67% -0.019 pp | 0.00% +0.003 pp | USD7.38 +132.8% | 24 qtrs — |
| 20 | CITADEL ADVISORS LLC | 394.6K +312.2K (+378.9%) | 6.78M +6.4M (+1,906.1%) | 0.60% +0.455 pp | 0.00% +0.001 pp | USD14.45 +18.9% | 38 qtrs — |
| 21 | MORGAN STANLEY | 386.2K -1.6M (-80.6%) | 6.63M -1.5M (-18.7%) | 0.58% -2.814 pp | 0.00% 0.000 pp | USD4.91 +249.9% | 51 qtrs — |
| 22 | BANK OF MONTREAL /CAN/ | 320.4K +320.4K (+100.0%) | 5.50M +5.5M (+100.0%) | 0.48% +0.484 pp | 0.00% +0.002 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 23 | TORONTO DOMINION BANK | 317.9K +292.9K (+1,171.6%) | 5.46M +5.4M (+5,226.8%) | 0.48% +0.437 pp | 0.01% +0.008 pp | USD16.15 +6.4% | 2 qtrs — |
| 24 | BADGLEY PHELPS WEALTH MANAGERS, LLC | 263.6K +— (+0.0%) | 4.53M +3.4M (+318.9%) | 0.40% -0.052 pp | 0.08% +0.060 pp | USD6.27 +174.0% | 11 qtrs — |
| 25 | BOOTHBAY FUND MANAGEMENT, LLC | 247.0K +247.0K (+100.0%) | 4.24M +4.2M (+100.0%) | 0.37% +0.373 pp | 0.06% +0.063 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 26 | JUMP FINANCIAL, LLC | 228.0K +228.0K (+100.0%) | 3.92M +3.9M (+100.0%) | 0.34% +0.344 pp | 0.05% +0.048 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 27 | GOLDMAN SACHS GROUP INC | 227.3K -108.8K (-32.4%) | 3.90M +2.5M (+183.3%) | 0.34% -0.231 pp | 0.00% +0.000 pp | USD4.46 +285.2% | 50 qtrs — |
| 28 | KOTLER KEVIN | 218.7K +218.7K (+100.0%) | 3.79M +3.8M (+100.0%) | 0.33% +0.330 pp | 0.89% +0.888 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 29 | EAM INVESTORS, LLC | 207.5K +207.5K (+100.0%) | 3.56M +3.6M (+100.0%) | 0.31% +0.313 pp | 0.40% +0.397 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 30 | WELLINGTON MANAGEMENT GROUP LLP | 202.6K +8.2K (+4.2%) | 3.48M +2.7M (+336.5%) | 0.31% -0.026 pp | 0.00% +0.001 pp | USD7.24 +137.3% | 8 qtrs — |
| 31 | KYNAM CAPITAL MANAGEMENT, LP | 200.0K +200.0K (+100.0%) | 3.44M +3.4M (+100.0%) | 0.30% +0.302 pp | 0.22% +0.220 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 32 | POLAR ASSET MANAGEMENT PARTNERS INC. | 200.0K -1.2M (-85.4%) | 3.44M -2.2M (-39.0%) | 0.30% -2.044 pp | 0.04% -0.020 pp | USD4.10 +319.0% | 2 qtrs — |
| 33 | ITAU UNIBANCO HOLDING S.A. | 180.0K +180.0K (+100.0%) | 3.05M +3.1M (+100.0%) | 0.27% +0.272 pp | 0.07% +0.073 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 34 | JANE STREET GROUP, LLC | 171.1K +133.3K (+352.6%) | 2.94M +2.8M (+1,796.1%) | 0.26% +0.194 pp | 0.00% +0.000 pp | USD14.29 +20.2% | 5 qtrs — |
| 35 | BANK OF NEW YORK MELLON CORP | 165.8K +3.4K (+2.1%) | 2.85M +2.2M (+327.8%) | 0.25% -0.027 pp | 0.00% +0.000 pp | USD6.23 +175.8% | 56 qtrs — |
| 36 | WELLS FARGO & COMPANY/MN | 165.3K +31.2K (+23.2%) | 2.84M +2.3M (+416.3%) | 0.25% +0.021 pp | 0.00% +0.000 pp | USD6.76 +154.1% | 50 qtrs — |
| 37 | INVESCO LTD. | 154.8K +32.7K (+26.8%) | 2.66M +2.2M (+431.1%) | 0.23% +0.025 pp | 0.00% +0.000 pp | USD8.12 +111.6% | 13 qtrs — |
| 38 | NUVEEN, LLC | 153.2K +65.6K (+74.8%) | 2.63M +2.3M (+632.4%) | 0.23% +0.082 pp | 0.00% +0.001 pp | USD12.06 +42.5% | 4 qtrs — |
| 39 | GROUP ONE TRADING, L.P. | 133.3K +35.0K (+35.6%) | 2.29M +1.9M (+467.9%) | 0.20% +0.033 pp | 0.00% +0.003 pp | USD7.71 +122.8% | 30 qtrs — |
| 40 | SIMPLEX TRADING, LLC | 124.0K +101.8K (+458.0%) | 2.13M +2.0M (+2,239.9%) | 0.19% +0.149 pp | 0.00% +0.001 pp | USD14.84 +15.8% | 8 qtrs — |
| 41 | BARCLAYS PLC | 120.5K +25.9K (+27.3%) | 2.07M +1.7M (+450.8%) | 0.18% +0.020 pp | 0.00% +0.000 pp | USD6.69 +156.8% | 51 qtrs — |
| 42 | AMERIPRISE FINANCIAL INC | 117.0K +468.0 (+0.4%) | 2.01M +1.5M (+320.6%) | 0.18% -0.022 pp | 0.00% +0.000 pp | USD3.34 +414.4% | 14 qtrs — |
| 43 | BANK OF AMERICA CORP /DE/ | 114.8K -160.6K (-58.3%) | 1.97M +842.6K (+74.6%) | 0.17% -0.297 pp | 0.00% +0.000 pp | USD3.70 +364.3% | 52 qtrs — |
| 44 | HIGHTOWER ADVISORS, LLC | 104.1K +8.9K (+9.3%) | 1.79M +1.4M (+358.0%) | 0.16% -0.005 pp | 0.00% +0.002 pp | USD7.85 +118.9% | 46 qtrs — |
| 45 | RHUMBLINE ADVISERS | 100.1K -5.8K (-5.4%) | 1.72M +1.3M (+296.1%) | 0.15% -0.030 pp | 0.00% +0.001 pp | USD4.96 +246.4% | 11 qtrs — |
| 46 | DIMENSIONAL FUND ADVISORS LP | 96.9K +96.9K (+100.0%) | 1.67M +1.7M (+100.0%) | 0.15% +0.146 pp | 0.00% +0.000 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 47 | PRICE T ROWE ASSOCIATES INC /MD/ | 95.7K +6.2K (+6.9%) | 1.64M +1.3M (+346.7%) | 0.14% -0.008 pp | 0.00% +0.000 pp | USD7.70 +123.1% | 28 qtrs — |
| 48 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 92.8K -78.3K (-45.8%) | 1.59M +891.7K (+127.1%) | 0.14% -0.152 pp | 0.02% +0.014 pp | USD3.19 +438.6% | 3 qtrs — |
| 49 | QUEST PARTNERS LLC | 82.6K +82.6K (+8,259,600.0%) | 1.42M +1.4M (+35,464,975.0%) | 0.12% +0.125 pp | 0.08% +0.079 pp | USD17.18 +0.0% | 5 qtrs — |
| 50 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 81.6K +63.4K (+348.1%) | 1.40M +1.3M (+1,769.3%) | 0.12% +0.092 pp | 0.00% +0.004 pp | USD14.70 +16.9% | 34 qtrs — |
| 51 | MML INVESTORS SERVICES, LLC | 77.9K +18.7K (+31.6%) | 1.34M +1.1M (+451.3%) | 0.12% +0.017 pp | 0.00% +0.003 pp | USD7.73 +122.3% | 7 qtrs — |
| 52 | TWO SIGMA ADVISERS, LP | 76.1K -502.1K (-86.8%) | 1.31M -1.1M (-44.9%) | 0.11% -0.872 pp | 0.00% -0.002 pp | USD3.33 +415.9% | 20 qtrs — |
| 53 | ALLIANCEBERNSTEIN L.P. | 73.5K +5.9K (+8.7%) | 1.26M +985.1K (+355.5%) | 0.11% -0.005 pp | 0.00% +0.000 pp | USD7.53 +128.2% | 11 qtrs — |
| 54 | CAPSTONE INVESTMENT ADVISORS, LLC | 66.3K -45.1K (-40.5%) | 1.14M +682.0K (+149.3%) | 0.10% -0.090 pp | 0.00% +0.001 pp | USD3.76 +356.9% | 3 qtrs — |
| 55 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 65.0K -64.4K (-49.8%) | 1.12M +585.1K (+110.3%) | 0.10% -0.123 pp | 0.01% +0.010 pp | USD3.20 +436.9% | 3 qtrs — |
| 56 | AMERICAN FINANCIAL GROUP INC | 64.1K +— (+0.0%) | 1.10M +838.3K (+318.9%) | 0.10% -0.013 pp | 0.40% +0.298 pp | USD8.96 +91.7% | 51 qtrs — |
| 57 | VERITION FUND MANAGEMENT LLC | 63.5K +63.5K (+100.0%) | 1.09M +1.1M (+100.0%) | 0.10% +0.096 pp | 0.00% +0.004 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 58 | ANCORA ADVISORS, LLC | 59.3K +56.3K (+1,875.0%) | 1.02M +1.0M (+8,173.3%) | 0.09% +0.084 pp | 0.02% +0.021 pp | USD16.79 +2.3% | 22 qtrs — |
| 59 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 56.7K +— (+0.0%) | 974.1K +741.5K (+318.9%) | 0.09% -0.011 pp | 0.02% +0.016 pp | USD3.51 +389.5% | 14 qtrs — |
| 60 | COLDSTREAM CAPITAL MANAGEMENT INC | 53.6K +27.8K (+107.5%) | 920.7K +814.8K (+769.3%) | 0.08% +0.037 pp | 0.01% +0.010 pp | USD10.22 +68.1% | 13 qtrs — |
| 61 | MINDSET WEALTH MANAGEMENT, LLC | 52.0K -8.0K (-13.3%) | 893.1K +647.1K (+263.0%) | 0.08% -0.024 pp | 0.23% +0.167 pp | USD4.24 +305.2% | 6 qtrs — |
| 62 | DEUTSCHE BANK AG\ | 48.7K +7.9K (+19.3%) | 836.6K +669.3K (+400.1%) | 0.07% +0.004 pp | 0.00% +0.000 pp | USD10.35 +66.0% | 50 qtrs — |
| 63 | WALLEYE TRADING LLC | 43.2K +43.2K (+100.0%) | 742.0K +742.0K (+100.0%) | 0.07% +0.065 pp | 0.00% +0.001 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 64 | CYPRESS CAPITAL GROUP | 42.0K +— (+0.0%) | 721.4K +549.2K (+318.9%) | 0.06% -0.008 pp | 0.08% +0.060 pp | USD5.52 +211.2% | 33 qtrs — |
| 65 | COMERICA BANK | 38.0K +3.0K (+8.6%) | 652.7K +509.2K (+354.8%) | 0.06% -0.002 pp | 0.00% +0.002 pp | USD5.00 +243.6% | 10 qtrs — |
| 66 | JPMORGAN CHASE & CO | 37.2K -379.0K (-91.1%) | 638.8K -1.1M (-62.6%) | 0.06% -0.654 pp | 0.00% 0.000 pp | USD4.30 +299.5% | 33 qtrs — |
| 67 | METLIFE INVESTMENT MANAGEMENT, LLC | 36.2K +15.7K (+76.6%) | 621.7K +537.7K (+639.6%) | 0.05% +0.020 pp | 0.00% +0.003 pp | USD10.20 +68.4% | 11 qtrs — |
| 68 | WALLEYE CAPITAL LLC | 35.0K +35.0K (+100.0%) | 601.1K +601.1K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.002 pp | USD17.18 +0.0% | 6 qtrs — |
| 69 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 34.3K -100.2K (-74.5%) | 589.3K +37.8K (+6.9%) | 0.05% -0.178 pp | 0.09% +0.009 pp | USD3.34 +414.4% | 3 qtrs — |
| 70 | SEI INVESTMENTS CO | 31.8K +18.7K (+142.2%) | 545.6K +491.8K (+914.7%) | 0.05% +0.026 pp | 0.00% +0.001 pp | USD13.27 +29.5% | 4 qtrs — |
| 71 | COLONY GROUP, LLC | 31.0K +31.0K (+100.0%) | 533.0K +533.0K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.001 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 72 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 30.6K +399.0 (+1.3%) | 525.3K +401.5K (+324.4%) | 0.05% -0.005 pp | 0.00% +0.001 pp | USD4.50 +281.8% | 7 qtrs — |
| 73 | CERITY PARTNERS LLC | 30.5K +1.8K (+6.1%) | 523.0K +405.3K (+344.4%) | 0.05% -0.003 pp | 0.00% +0.001 pp | USD4.73 +263.2% | 21 qtrs — |
| 74 | INTECH INVESTMENT MANAGEMENT LLC | 30.0K +4.3K (+16.9%) | 514.7K +409.5K (+389.5%) | 0.05% +0.002 pp | 0.00% +0.004 pp | USD9.37 +83.4% | 5 qtrs — |
| 75 | AXQ CAPITAL, LP | 29.2K +29.2K (+100.0%) | 500.7K +500.7K (+100.0%) | 0.04% +0.044 pp | 0.11% +0.113 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 76 | CITIGROUP INC | 27.5K +22.0K (+398.3%) | 472.1K +449.5K (+1,987.2%) | 0.04% +0.032 pp | 0.00% +0.000 pp | USD14.68 +17.0% | 54 qtrs — |
| 77 | MAN GROUP PLC | 27.1K +27.1K (+100.0%) | 465.4K +465.4K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.001 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 78 | VIRTUS INVESTMENT ADVISERS, INC. | 26.2K +26.2K (+100.0%) | 450.2K +450.2K (+100.0%) | 0.04% +0.040 pp | 0.12% +0.122 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 79 | QUANTINNO CAPITAL MANAGEMENT LP | 25.1K +6.9K (+37.7%) | 430.6K +356.0K (+476.9%) | 0.04% +0.007 pp | 0.00% +0.001 pp | USD7.68 +123.7% | 2 qtrs — |
| 80 | ADAR1 CAPITAL MANAGEMENT, LLC | 25.0K +25.0K (+100.0%) | 429.4K +429.4K (+100.0%) | 0.04% +0.038 pp | 0.03% +0.032 pp | USD17.18 +0.0% | 1 qtrs NEW |
| 81 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 31.7K +2.6K (+9.0%) | 429.3K +300.1K (+232.3%) | 0.05% -0.002 pp | 0.00% +0.000 pp | USD8.58 +100.2% | 4 qtrs — |
| 82 | LOS ANGELES CAPITAL MANAGEMENT LLC | 30.9K +30.9K (+100.0%) | 232.5K +232.5K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.001 pp | USD17.18 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 79 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Biotechnology & Genome ETF PBE | 2.15% | 6.15M | 0.58% |
| 2 | Virtus Biotech ETF BBP | 1.52% | 1.49M | 0.34% |
| 3 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.46% | 6.88M | 0.35% |
| 4 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.46% | 102.1K | 0.20% |
| 5 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.30% | 70.6K | 1.22% |
| 6 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.26% | 426.7K | 0.51% |
| 7 | iShares U.S. Pharmaceuticals ETF IHE | 0.17% | 2.24M | 0.38% |
| 8 | iShares Micro-Cap ETF IWC | 0.17% | 2.48M | 0.60% |
| 9 | Vanguard U.S. Momentum Factor ETF VFMO | 0.08% | 1.35M | 0.13% |
| 10 | Vanguard Global Momentum Factor ETF VMO.TO | 0.06% | 204.5K | 0.38% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.33
Bearish
Ratio by volume
0.33
Bearish
Buys
1
Sells
3
Shares acquired
30.0K
Shares disposed
90.0K
Cash buys
—
Cash sales
2.00
Net activity
-60,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | Demopulos Gregory A MD | Director / Officer | M-Exempt | A | Common stock | 400,000 | 10.27 | 4.11M | 1,826,986 | D | ↗ |
| 2026-01-13 | Borges David J. | Officer | M-Exempt | D | Stock Option (right to buy) | 30,000 | 3.06 | 91.8K | 65,000 | D | ↗ |
| 2026-01-12 | Borges David J. | Officer | S-Sale | D | Common stock | 30,000 | 12.72 | 381.6K | 0 | D | ↗ |
| 2025-10-13 | Demopulos Gregory A MD | Director / Officer | G-Gift | D | Common Stock | 600,000 | 0.00 | — | 1,426,986 | D | ↗ |
| 2025-06-30 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 865,000 | 3.20 | 2.77M | 865,000 | D | ↗ |
| 2025-06-30 | Cancelmo Peter B | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 3.20 | 320.0K | 100,000 | D | ↗ |
| 2025-06-30 | Borges David J. | Officer | A-Award | A | Stock Option (right to buy) | 95,000 | 3.20 | 304.0K | 95,000 | D | ↗ |
| 2025-06-27 | Shah Rajiv | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.20 | 48.0K | 15,000 | D | ↗ |
| 2025-06-27 | Perkinson Diana T. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.20 | 48.0K | 15,000 | D | ↗ |
| 2025-06-27 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.20 | 48.0K | 15,000 | D | ↗ |
| 2025-06-27 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.20 | 48.0K | 15,000 | D | ↗ |
| 2025-06-27 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.20 | 48.0K | 15,000 | D | ↗ |
| 2025-06-27 | Cable Thomas J. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.20 | 48.0K | 15,000 | D | ↗ |
| 2025-06-27 | Bumol Thomas F. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.20 | 48.0K | 15,000 | D | ↗ |
| 2024-06-30 | Borges David J. | Officer | — | D | Common Stock | 0 | 0.00 | — | 30,000 | — | ↗ |
| 2024-06-06 | Shah Rajiv | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.91 | 58.7K | 15,000 | — | ↗ |
| 2024-06-06 | Perkinson Diana T. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.91 | 58.7K | 15,000 | — | ↗ |
| 2024-06-06 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.91 | 58.7K | 15,000 | — | ↗ |
| 2024-06-06 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.91 | 58.7K | 15,000 | — | ↗ |
| 2024-06-06 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.91 | 58.7K | 15,000 | — | ↗ |
| 2024-06-06 | Cable Thomas J. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.91 | 58.7K | 15,000 | — | ↗ |
| 2024-06-06 | Bumol Thomas F. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.91 | 58.7K | 15,000 | — | ↗ |
| 2024-04-25 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 3.06 | 306.0K | 100,000 | — | ↗ |
| 2024-04-25 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 725,000 | 3.06 | 2.22M | 725,000 | — | ↗ |
| 2024-04-25 | Cancelmo Peter B | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 3.06 | 306.0K | 100,000 | — | ↗ |
| 2023-11-17 | Demopulos Gregory A MD | Officer | P-Purchase | A | Common Stock | 15,000 | 1.68 | 25.2K | 123,945 | — | ↗ |
| 2023-11-15 | Demopulos Peter A MD | Director | P-Purchase | A | Common Stock | 10,000 | 1.53 | 15.3K | 208,516 | — | ↗ |
| 2023-11-14 | Demopulos Gregory A MD | Officer | A-Award | A | Common Stock | 25,000 | 1.44 | 36.0K | 108,945 | — | ↗ |
| 2023-11-13 | Demopulos Gregory A MD | Officer | A-Award | A | Common Stock | 37,500 | 1.29 | 48.4K | 83,945 | — | ↗ |
| 2023-09-22 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 2.94 | 294.0K | 100,000 | — | ↗ |
| 2023-09-22 | Demopulos Gregory A MD | Officer | A-Award | A | Stock Option (right to buy) | 715,000 | 2.94 | 2.10M | 715,000 | — | ↗ |
| 2023-09-22 | Cancelmo Peter B | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 2.94 | 294.0K | 100,000 | — | ↗ |
| 2023-09-12 | Bumol Thomas F. | Director | A-Award | A | Common Stock | 10,000 | 3.31 | 33.1K | 10,000 | — | ↗ |
| 2023-06-23 | Shah Rajiv | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.49 | 82.4K | 15,000 | — | ↗ |
| 2023-06-23 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.49 | 82.4K | 15,000 | — | ↗ |
| 2023-06-23 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.49 | 82.4K | 15,000 | — | ↗ |
| 2023-06-23 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.49 | 82.4K | 15,000 | — | ↗ |
| 2023-06-23 | Cable Thomas J. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.49 | 82.4K | 15,000 | — | ↗ |
| 2023-06-23 | Bumol Thomas F. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.49 | 82.4K | 15,000 | — | ↗ |
| 2023-05-22 | HANISH ARNOLD C | Director | M-Exempt | A | Common Stock | 5,000 | 5.30 | 26.5K | 5,000 | — | ↗ |
| 2023-05-22 | Cable Thomas J. | Director | M-Exempt | A | Common Stock | 5,000 | 5.30 | 26.5K | 40,067 | — | ↗ |
| 2023-05-12 | Perkinson Diana T. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 5.71 | 171.3K | 30,000 | — | ↗ |
| 2022-09-21 | Zumwalt Kurt | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 3.93 | 29.5K | 7,500 | — | ↗ |
| 2022-09-21 | Shah Rajiv | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 3.93 | 29.5K | 7,500 | — | ↗ |
| 2022-09-21 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (right to buy) | 85,000 | 3.93 | 334.1K | 85,000 | — | ↗ |
| 2022-09-21 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 3.93 | 29.5K | 7,500 | — | ↗ |
| 2022-09-21 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 3.93 | 29.5K | 7,500 | — | ↗ |
| 2022-09-21 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 3.93 | 29.5K | 7,500 | — | ↗ |
| 2022-09-21 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 650,000 | 3.93 | 2.55M | 650,000 | — | ↗ |
| 2022-09-21 | Cancelmo Peter B | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 3.93 | 314.4K | 80,000 | — | ↗ |
| 2022-09-21 | Cable Thomas J. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 3.93 | 29.5K | 7,500 | — | ↗ |
| 2022-09-21 | Bumol Thomas F. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 3.93 | 29.5K | 7,500 | — | ↗ |
| 2022-06-17 | Zumwalt Kurt | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-06-17 | Shah Rajiv | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-06-17 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-06-17 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 2.00 | 15.0K | 7,500 | — | ↗ |
| 2022-06-17 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 2.00 | 15.0K | 7,500 | — | ↗ |
| 2022-06-17 | Cable Thomas J. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-06-17 | Bumol Thomas F. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 2.00 | 15.0K | 7,500 | — | ↗ |
| 2021-09-08 | HANISH ARNOLD C | Director | M-Exempt | A | Common Stock | 10,000 | 9.44 | 94.4K | 10,000 | — | ↗ |
| 2021-07-02 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 14.99 | 1.12M | 75,000 | — | ↗ |
| 2021-07-02 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 550,000 | 14.99 | 8.24M | 550,000 | — | ↗ |
| 2021-07-02 | Cancelmo Peter B | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 14.99 | 1.12M | 75,000 | — | ↗ |
| 2021-06-17 | Demopulos Gregory A MD | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 36,857 | 4.10 | 151.1K | 0 | — | ↗ |
| 2021-06-15 | Demopulos Gregory A MD | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 36,856 | 4.10 | 151.1K | 36,857 | — | ↗ |
| 2021-06-11 | Zumwalt Kurt | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 15.81 | 118.6K | 7,500 | — | ↗ |
| 2021-06-11 | Shah Rajiv | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 15.81 | 118.6K | 7,500 | — | ↗ |
| 2021-06-11 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 15.81 | 118.6K | 7,500 | — | ↗ |
| 2021-06-11 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 15.81 | 118.6K | 7,500 | — | ↗ |
| 2021-06-11 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 15.81 | 118.6K | 7,500 | — | ↗ |
| 2021-06-11 | Cable Thomas J. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 15.81 | 118.6K | 7,500 | — | ↗ |
| 2021-06-11 | Bumol Thomas F. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 15.81 | 118.6K | 7,500 | — | ↗ |
| 2021-06-11 | Aspiri Ray | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 15.81 | 118.6K | 7,500 | — | ↗ |
| 2021-05-20 | Demopulos Gregory A MD | Director / Officer | M-Exempt | A | Common Stock | 36,856 | 4.10 | 151.1K | 2,063,842 | — | ↗ |
| 2021-05-19 | Demopulos Gregory A MD | Director / Officer | M-Exempt | A | Common Stock | 36,857 | 4.10 | 151.1K | 2,063,843 | — | ↗ |
| 2021-04-08 | Demopulos Gregory A MD | Director / Officer | M-Exempt | A | Common Stock | 35,206 | 4.10 | 144.3K | 2,062,192 | — | ↗ |
| 2021-04-07 | Demopulos Gregory A MD | Director / Officer | M-Exempt | A | Common Stock | 37,407 | 4.10 | 153.4K | 2,064,393 | — | ↗ |
| 2021-02-22 | JACOBSEN MICHAEL A | Officer | M-Exempt | A | Common Stock | 8,100 | 10.27 | 83.2K | 22,100 | — | ↗ |
| 2021-02-22 | Demopulos Peter A MD | Director | M-Exempt | A | Common Stock | 5,000 | 4.53 | 22.7K | 198,516 | — | ↗ |
| 2021-02-19 | JACOBSEN MICHAEL A | Officer | S-Sale | D | Common Stock | 10,000 | 22.64 | 226.4K | 14,000 | — | ↗ |
| 2021-02-12 | Hood Leroy E. MD PhD | Director | M-Exempt | A | Common Stock | 5,000 | 4.53 | 22.7K | 74,390 | — | ↗ |
| 2021-02-10 | JACOBSEN MICHAEL A | Officer | M-Exempt | A | Common Stock | 1,900 | 10.27 | 19.5K | 15,900 | — | ↗ |
| 2021-01-20 | JACOBSEN MICHAEL A | Officer | M-Exempt | A | Common Stock | 10,000 | 9.37 | 93.7K | 14,000 | — | ↗ |
| 2021-01-19 | JACOBSEN MICHAEL A | Officer | S-Sale | D | Common Stock | 9,500 | 19.95 | 189.5K | 4,000 | — | ↗ |
| 2021-01-13 | Cable Thomas J. | Director | M-Exempt | A | Common Stock | 5,000 | 4.53 | 22.7K | 40,067 | — | ↗ |
| 2020-10-26 | Cancelmo Peter B | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 10.22 | 204.4K | 20,000 | — | ↗ |
| 2020-06-05 | Shah Rajiv | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 14.66 | 110.0K | 7,500 | — | ↗ |
| 2020-06-05 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 14.66 | 110.0K | 7,500 | — | ↗ |
| 2020-06-05 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 14.66 | 110.0K | 7,500 | — | ↗ |
| 2020-06-05 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 14.66 | 110.0K | 7,500 | — | ↗ |
| 2020-06-05 | Cable Thomas J. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 14.66 | 110.0K | 7,500 | — | ↗ |
| 2020-06-05 | Bumol Thomas F. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 14.66 | 110.0K | 7,500 | — | ↗ |
| 2020-06-05 | Aspiri Ray | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 14.66 | 110.0K | 7,500 | — | ↗ |
| 2020-05-13 | Cable Thomas J. | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 5.92 | 29.6K | 0 | — | ↗ |
| 2020-03-13 | Hood Leroy E. MD PhD | Director | M-Exempt | A | Common Stock | 5,000 | 5.92 | 29.6K | 69,390 | — | ↗ |
| 2020-03-01 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 11.91 | 833.7K | 70,000 | — | ↗ |
| 2020-03-01 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 11.91 | 5.36M | 450,000 | — | ↗ |
| 2020-03-01 | Cancelmo Peter B | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 11.91 | 595.5K | 50,000 | — | ↗ |
| 2020-02-10 | Zumwalt Kurt | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 12.73 | 191.0K | 15,000 | — | ↗ |
| 2019-12-14 | Hood Leroy E. MD PhD | Director | M-Exempt | A | Common Stock | 10,000 | 7.56 | 75.6K | 64,390 | — | ↗ |
| 2019-12-14 | Demopulos Peter A MD | Director | M-Exempt | A | Common Stock | 3,334 | 7.56 | 25.2K | 188,516 | — | ↗ |
| 2019-12-03 | Cable Thomas J. | Director | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 7.56 | 75.6K | 0 | — | ↗ |
| 2019-10-14 | Cable Thomas J. | Director | S-Sale | D | Common Stock | 5,000 | 15.12 | 75.6K | 35,067 | — | ↗ |
| 2019-06-10 | Cancelmo Peter B | Officer | A-Award | A | Stock Option(Right to Buy) | 20,000 | 16.63 | 332.6K | 20,000 | — | ↗ |
| 2019-06-07 | Shah Rajiv | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 16.87 | 126.5K | 7,500 | — | ↗ |
| 2019-06-07 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 10,000 | 6.05 | 60.5K | 210,645 | — | ↗ |
| 2019-06-07 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 16.87 | 126.5K | 7,500 | — | ↗ |
| 2019-06-07 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 16.87 | 126.5K | 7,500 | — | ↗ |
| 2019-06-07 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 16.87 | 126.5K | 7,500 | — | ↗ |
| 2019-06-07 | Cable Thomas J. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 16.87 | 126.5K | 7,500 | — | ↗ |
| 2019-06-07 | Aspiri Ray | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 16.87 | 126.5K | 7,500 | — | ↗ |
| 2019-02-09 | Bumol Thomas F. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-08 | Kelbon Marcia S. | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 13.45 | 874.3K | 65,000 | — | ↗ |
| 2019-02-08 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 13.45 | 874.3K | 65,000 | — | ↗ |
| 2019-02-08 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 425,000 | 13.45 | 5.72M | 425,000 | — | ↗ |
| 2018-08-31 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 8,000 | 6.05 | 48.4K | 200,645 | — | ↗ |
| 2018-08-30 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 35,000 | 4.10 | 143.5K | 227,645 | — | ↗ |
| 2018-07-27 | Kelbon Marcia S. | Officer | S-Sale | D | Common Stock | 5,723 | 21.73 | 124.4K | 192,645 | — | ↗ |
| 2018-07-26 | Kelbon Marcia S. | Officer | S-Sale | D | Common Stock | 35,000 | 21.53 | 753.7K | 184,645 | — | ↗ |
| 2018-07-12 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 4,277 | 4.10 | 17.5K | 188,922 | — | ↗ |
| 2018-06-15 | Shah Rajiv | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 19.91 | 149.3K | 7,500 | — | ↗ |
| 2018-06-15 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 19.91 | 149.3K | 7,500 | — | ↗ |
| 2018-06-15 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 19.91 | 149.3K | 7,500 | — | ↗ |
| 2018-06-15 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 19.91 | 149.3K | 7,500 | — | ↗ |
| 2018-06-15 | Cable Thomas J. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 19.91 | 149.3K | 7,500 | — | ↗ |
| 2018-06-15 | Aspiri Ray | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 19.91 | 149.3K | 7,500 | — | ↗ |
| 2018-05-15 | JACOBSEN MICHAEL A | Officer | M-Exempt | A | Common Stock | 12,812 | 9.37 | 120.0K | 21,312 | — | ↗ |
| 2018-05-14 | JACOBSEN MICHAEL A | Officer | M-Exempt | A | Common Stock | 10,980 | 9.37 | 102.9K | 19,480 | — | ↗ |
| 2018-04-08 | Kelbon Marcia S. | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 13.58 | 882.7K | 65,000 | — | ↗ |
| 2018-04-08 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 13.58 | 814.8K | 60,000 | — | ↗ |
| 2018-04-08 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 13.58 | 4.75M | 350,000 | — | ↗ |
| 2018-01-04 | JACOBSEN MICHAEL A | Officer | M-Exempt | A | Common Stock | 1,000 | 9.37 | 9.4K | 8,500 | — | ↗ |
| 2018-01-03 | Kelbon Marcia S. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 62,528 | 9.37 | 585.9K | 40,972 | — | ↗ |
| 2018-01-03 | JACOBSEN MICHAEL A | Officer | S-Sale | D | Common Stock | 1,020 | 22.45 | 22.9K | 7,500 | — | ↗ |
| 2017-12-28 | Demopulos Gregory A MD | Director / Officer | M-Exempt | A | Common Stock | 39,961 | 4.10 | 163.8K | 2,026,986 | — | ↗ |
| 2017-08-21 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 8,000 | 6.05 | 48.4K | 176,641 | — | ↗ |
| 2017-06-16 | Shah Rajiv | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 23.75 | 237.5K | 10,000 | — | ↗ |
| 2017-06-16 | JACOBSEN MICHAEL A | Officer | M-Exempt | A | Common Stock | 14,000 | 9.37 | 131.2K | 19,500 | — | ↗ |
| 2017-06-16 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 23.75 | 237.5K | 10,000 | — | ↗ |
| 2017-06-16 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 23.75 | 237.5K | 10,000 | — | ↗ |
| 2017-06-16 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 23.75 | 237.5K | 10,000 | — | ↗ |
| 2017-06-16 | Cable Thomas J. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 23.75 | 237.5K | 10,000 | — | ↗ |
| 2017-06-16 | Aspiri Ray | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 23.75 | 237.5K | 10,000 | — | ↗ |
| 2017-06-15 | JACOBSEN MICHAEL A | Officer | M-Exempt | A | Common Stock | 14,000 | 9.37 | 131.2K | 17,500 | — | ↗ |
| 2017-06-14 | JACOBSEN MICHAEL A | Officer | S-Sale | D | Common Stock | 9,350 | 19.95 | 186.5K | 3,500 | — | ↗ |
| 2017-06-13 | JACOBSEN MICHAEL A | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,650 | 9.37 | 24.8K | 100,850 | — | ↗ |
| 2017-04-12 | Cable Thomas J. | Director | S-Sale | D | Common Stock | 3,000 | 16.49 | 49.5K | 40,067 | — | ↗ |
| 2017-03-20 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 2,040 | 6.05 | 12.3K | 168,641 | — | ↗ |
| 2017-02-26 | Kelbon Marcia S. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 11.55 | 866.3K | 75,000 | — | ↗ |
| 2017-02-26 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 11.55 | 808.5K | 70,000 | — | ↗ |
| 2017-02-26 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 11.55 | 4.33M | 375,000 | — | ↗ |
| 2016-12-14 | Cable Thomas J. | Director | S-Sale | D | Common Stock | 3,000 | 10.21 | 30.6K | 43,067 | — | ↗ |
| 2016-12-07 | Demopulos Gregory A MD | Director / Officer | M-Exempt | A | Common Stock | 102,044 | 0.98 | 100.0K | 1,987,029 | — | ↗ |
| 2016-12-06 | Demopulos Gregory A MD | Director / Officer | M-Exempt | A | Common Stock | 102,040 | 0.98 | 100.0K | 1,987,025 | — | ↗ |
| 2016-12-05 | Kelbon Marcia S. | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 10.56 | 844.8K | 80,000 | — | ↗ |
| 2016-12-05 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 10.56 | 897.6K | 85,000 | — | ↗ |
| 2016-12-05 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 10.56 | 4.22M | 400,000 | — | ↗ |
| 2016-12-02 | Demopulos Gregory A MD | Director / Officer | M-Exempt | A | Common Stock | 181,163 | 0.98 | 177.5K | 1,884,985 | — | ↗ |
| 2016-12-01 | Demopulos Gregory A MD | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 106,521 | 0.98 | 104.4K | 408,164 | — | ↗ |
| 2016-11-30 | Demopulos Gregory A MD | Director / Officer | S-Sale | D | Common Stock | 97,559 | 12.21 | 1.19M | 1,703,822 | — | ↗ |
| 2016-10-12 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 3,004 | 6.05 | 18.2K | 166,601 | — | ↗ |
| 2016-09-15 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 16,000 | 0.98 | 15.7K | 179,597 | — | ↗ |
| 2016-08-15 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 15,900 | 0.98 | 15.6K | 179,497 | — | ↗ |
| 2016-08-12 | Cable Thomas J. | Director | S-Sale | D | Common Stock | 3,000 | 11.52 | 34.6K | 46,067 | — | ↗ |
| 2016-07-15 | Kelbon Marcia S. | Officer | S-Sale | D | Common Stock | 15,900 | 11.50 | 182.8K | 163,597 | — | ↗ |
| 2016-06-15 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 15,900 | 0.98 | 15.6K | 179,497 | — | ↗ |
| 2016-06-09 | Shah Rajiv | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 10.84 | 81.3K | 7,500 | — | ↗ |
| 2016-06-09 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 10.84 | 81.3K | 7,500 | — | ↗ |
| 2016-06-09 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 10.84 | 81.3K | 7,500 | — | ↗ |
| 2016-06-09 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 10.84 | 81.3K | 7,500 | — | ↗ |
| 2016-06-09 | Cable Thomas J. | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 10.84 | 81.3K | 7,500 | — | ↗ |
| 2016-06-09 | Aspiri Ray | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 10.84 | 81.3K | 7,500 | — | ↗ |
| 2016-05-16 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 15,900 | 0.98 | 15.6K | 179,497 | — | ↗ |
| 2016-04-15 | Kelbon Marcia S. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,900 | 0.98 | 15.6K | 79,600 | — | ↗ |
| 2016-03-24 | Cable Thomas J. | Director | S-Sale | D | Common Stock | 1,600 | 14.71 | 23.5K | 49,467 | — | ↗ |
| 2016-03-23 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 15,171 | 4.10 | 62.2K | 163,597 | — | ↗ |
| 2016-03-15 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 15,900 | 0.98 | 15.6K | 164,326 | — | ↗ |
| 2016-03-08 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 31,800 | 0.98 | 31.2K | 180,226 | — | ↗ |
| 2016-02-19 | Kelbon Marcia S. | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 10.27 | 821.6K | 80,000 | — | ↗ |
| 2016-02-19 | JACOBSEN MICHAEL A | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 10.27 | 873.0K | 85,000 | — | ↗ |
| 2016-02-19 | Demopulos Gregory A MD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 10.27 | 4.11M | 400,000 | — | ↗ |
| 2016-01-14 | Kelbon Marcia S. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 4.10 | 41.0K | 102,700 | — | ↗ |
| 2016-01-14 | Demopulos Gregory A MD | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 100,000 | 0.98 | 98.0K | 181,163 | — | ↗ |
| 2015-12-22 | Kelbon Marcia S. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 746 | 0.98 | 731.08 | 143,200 | — | ↗ |
| 2015-12-19 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 7,300 | 4.10 | 29.9K | 138,426 | — | ↗ |
| 2015-12-18 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 15,154 | 0.98 | 14.9K | 146,280 | — | ↗ |
| 2015-11-23 | Kelbon Marcia S. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,900 | 0.98 | 15.6K | 159,100 | — | ↗ |
| 2015-11-18 | Cable Thomas J. | Director | S-Sale | D | Common Stock | 2,000 | 13.73 | 27.5K | 51,067 | — | ↗ |
| 2015-09-04 | Demopulos Peter A MD | Director | P-Purchase | A | Common Stock | 3,962 | 12.68 | 50.2K | 185,182 | — | ↗ |
| 2015-08-18 | Demopulos Gregory A MD | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 12,000 | 0.98 | 11.8K | 281,163 | — | ↗ |
| 2015-07-15 | Cable Thomas J. | Director | S-Sale | D | Common Stock | 2,000 | 18.78 | 37.6K | 53,067 | — | ↗ |
| 2015-07-07 | Kelbon Marcia S. | Officer | M-Exempt | A | Common Stock | 5,102 | 2.45 | 12.5K | 131,126 | — | ↗ |
| 2015-06-14 | Shah Rajiv | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 19.67 | 295.1K | 15,000 | — | ↗ |
| 2015-05-22 | Hood Leroy E. MD PhD | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 21.20 | 106.0K | 5,000 | — | ↗ |
| 2015-05-22 | HANISH ARNOLD C | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 21.20 | 106.0K | 5,000 | — | ↗ |
| 2015-05-22 | Demopulos Peter A MD | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 21.20 | 106.0K | 5,000 | — | ↗ |
| 2015-05-22 | Cable Thomas J. | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 21.20 | 106.0K | 5,000 | — | ↗ |
| 2015-05-22 | Aspiri Ray | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 21.20 | 106.0K | 5,000 | — | ↗ |
| 2015-03-24 | Cable Thomas J. | Director | S-Sale | D | Common Stock | 1,790 | 24.43 | 43.7K | 55,277 | — | ↗ |
| 2015-01-28 | Demopulos Gregory A MD | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 32,000 | 0.98 | 31.4K | 1,591,822 | — | ↗ |
Executive team
Top executives
Shares Outstanding
72.00M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board | 972.5K | 972.5K | — | 2.21M | — | 25.0K | 4.18M | 52.85% | ↗ |
| 2 | 2025 | Peter B. Cancelmo, J.D. Vice President, General Counsel and Secretary | 489.5K | 171.3K | — | 255.3K | — | 4.6K | 920.7K | 27.72% | ↗ |
| 3 | 2025 | David J. Borges Vice President, Finance, Chief Accounting Officer and Treasurer | 325.6K | 113.8K | — | 242.5K | — | 4.4K | 686.3K | 35.33% | ↗ |
| 4 | 2024 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board | 960.9K | 926.2K | — | 1.85M | — | 25.2K | 3.76M | 49.19% | ↗ |
| 5 | 2024 | Peter B. Cancelmo, J.D. Vice President, General Counsel and Secretary | 483.7K | 163.2K | — | 255.4K | — | 4.7K | 906.9K | 28.16% | ↗ |
| 6 | 2024 | Michael A. Jacobson Former Vice President, Finance, Chief Accounting Officer and Treasurer | 275.4K | 161.0K | — | 255.4K | — | 4.2K | 696.0K | 36.70% | ↗ |
| 7 | 2024 | David J. Borges Vice President, Finance, Chief Accounting Officer and Treasurer | 311.8K | 69.0K | — | 242.6K | — | 4.4K | 627.9K | 38.64% | ↗ |
| 8 | 2023 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board | 917.3K | 5.02M | — | 1.72M | — | 23.8K | 7.69M | 22.43% | ↗ |
| 9 | 2023 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 454.5K | 151.1K | — | 241.2K | — | 7.2K | 854.0K | 28.24% | ↗ |
| 10 | 2023 | Michael A. Jacobson Former Vice President, Finance, Chief Accounting Officer and Treasurer | 454.5K | 151.1K | — | 241.2K | — | 7.2K | 854.0K | 28.24% | ↗ |
| 11 | 2023 | Peter B. Cancelmo, J.D. Vice President, General Counsel and Secretary | 456.5K | 147.6K | — | 241.2K | — | 7.3K | 852.6K | 28.29% | ↗ |
| 12 | 2022 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board | 882.0K | 890.0K | — | 1.93M | — | 22.6K | 3.73M | 51.87% | ↗ |
| 13 | 2022 | Michael A. Jacobson Former Vice President, Finance, Chief Accounting Officer and Treasurer | 429.9K | 81.1K | — | 252.9K | — | 7.5K | 771.5K | 32.78% | ↗ |
| 14 | 2022 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 429.9K | 81.1K | — | 252.9K | — | 7.5K | 771.5K | 32.78% | ↗ |
| 15 | 2022 | Peter B. Cancelmo, J.D. Vice President, General Counsel and Secretary | 418.0K | 77.8K | — | 238.0K | — | 7.5K | 741.3K | 32.11% | ↗ |
| 16 | 2021 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board | 848.1K | 875.0K | — | 5.67M | — | 21.6K | 7.42M | 76.47% | ↗ |
| 17 | 2021 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 401.7K | 97.0K | — | 773.3K | — | 6.6K | 1.28M | 60.48% | ↗ |
| 18 | 2021 | Peter B. Cancelmo, J.D. Vice President, General Counsel and Secretary | 381.6K | 90.0K | — | 773.3K | — | 6.6K | 1.25M | 61.79% | ↗ |
| 19 | 2020 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board | 817.4K | 1.40M | — | 3.54M | — | 20.7K | 5.78M | 61.25% | ↗ |
| 20 | 2020 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 384.0K | 153.2K | — | 550.2K | — | 6.6K | 1.09M | 50.30% | ↗ |
| 21 | 2020 | Peter B. Cancelmo, J.D. Vice President, General Counsel and Secretary | 345.0K | 57.5K | — | 534.6K | — | 6.6K | 943.7K | 56.65% | ↗ |
| 22 | 2019 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 793.6K | — | — | 4.01M | — | 20.2K | 4.83M | 83.13% | ↗ |
| 23 | 2019 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board | 793.6K | — | — | 4.01M | — | 20.2K | 4.83M | 83.13% | ↗ |
| 24 | 2019 | Marcia S. Kelbon, J.D., M.S. Former Vice President, Patents, General Counsel and Secretary | 409.0K | 90.0K | — | 613.5K | — | 6.6K | 1.12M | 54.82% | ↗ |
| 25 | 2019 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 363.4K | — | — | 613.5K | — | 6.6K | 983.5K | 62.38% | ↗ |
| 26 | 2019 | Peter B. Cancelmo, J.D. Vice President, General Counsel and Secretary | 287.5K | 15.0K | — | 398.0K | — | 5.4K | 706.0K | 56.38% | ↗ |
| 27 | 2018 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 770.5K | 700.0K | — | 3.25M | — | 19.6K | 4.74M | 68.57% | ↗ |
| 28 | 2018 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board | 770.5K | 700.0K | — | 3.25M | — | 19.6K | 4.74M | 68.57% | ↗ |
| 29 | 2018 | Marcia S. Kelbon, J.D., M.S. Former Vice President, Patents, General Counsel and Secretary | 397.1K | 77.7K | — | 603.6K | — | 6.7K | 1.09M | 55.63% | ↗ |
| 30 | 2018 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 397.1K | 77.7K | — | 603.6K | — | 6.7K | 1.09M | 55.63% | ↗ |
| 31 | 2018 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 352.8K | 69.0K | — | 557.2K | — | 6.6K | 985.6K | 56.53% | ↗ |
| 32 | 2017 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 748.0K | 901.7K | — | 2.86M | — | 20.6K | 4.54M | 63.17% | ↗ |
| 33 | 2017 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 381.3K | 258.1K | — | 573.0K | — | 6.7K | 1.22M | 47.00% | ↗ |
| 34 | 2017 | Marcia S. Kelbon, J.D., M.S. Former Vice President, Patents, General Counsel and Secretary | 381.3K | 258.1K | — | 573.0K | — | 6.7K | 1.22M | 47.00% | ↗ |
| 35 | 2017 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 338.8K | 136.2K | — | 534.8K | — | 6.6K | 1.02M | 52.62% | ↗ |
| 36 | 2016 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 776.9K | 248.6K | — | 5.34M | — | 15.2K | 6.38M | 83.69% | ↗ |
| 37 | 2016 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 400.4K | 64.1K | — | 1.07M | — | 2.6K | 1.54M | 69.57% | ↗ |
| 38 | 2016 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 336.8K | 51.9K | — | 1.13M | — | 2.6K | 1.53M | 74.36% | ↗ |
| 39 | 2015 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 669.5K | — | — | — | — | 14.1K | 683.6K | 0.00% | ↗ |
| 40 | 2015 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 345.1K | — | — | — | — | 2.6K | 347.7K | 0.00% | ↗ |
| 41 | 2015 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 285.0K | — | — | — | — | 2.5K | 287.5K | 0.00% | ↗ |
| 42 | 2014 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 684.1K | — | — | 3.24M | — | 17.2K | 3.94M | 82.19% | ↗ |
| 43 | 2014 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 684.1K | — | — | — | — | 17.2K | 3.94M | 0.00% | ↗ |
| 44 | 2014 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 352.6K | — | — | 791.2K | — | 2.5K | 1.15M | 69.03% | ↗ |
| 45 | 2014 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 352.6K | — | — | — | — | 2.5K | 1.15M | 0.00% | ↗ |
| 46 | 2014 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 285.0K | — | — | 719.7K | — | 2.4K | 1.01M | 71.46% | ↗ |
| 47 | 2014 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 285.0K | — | — | — | — | 2.4K | 1.01M | 0.00% | ↗ |
| 48 | 2013 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 650.0K | — | — | — | — | 14.9K | 3.24M | 0.00% | ↗ |
| 49 | 2013 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 650.0K | — | — | 2.57M | — | 14.9K | 3.24M | 79.46% | ↗ |
| 50 | 2013 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 335.0K | — | — | — | — | 2.2K | 1.04M | 0.00% | ↗ |
| 51 | 2013 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 335.0K | — | — | 700.4K | — | 2.2K | 1.04M | 67.51% | ↗ |
| 52 | 2013 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 79.7K | — | — | — | — | 717.00 | 787.2K | 0.00% | ↗ |
| 53 | 2013 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | 79.7K | — | — | 706.8K | — | 717.00 | 787.2K | 89.78% | ↗ |
| 54 | 2012 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 655.5K | 108.2K | — | — | — | 18.3K | 3.53M | 0.00% | ↗ |
| 55 | 2012 | Gregory A. Demopulos, M.D. President, Chief Executive Officer, Chairman of the Board of Directors and Interim Chief Financial Officer and Treasurer | 655.5K | 108.2K | — | 2.75M | — | 18.3K | 3.53M | 77.88% | ↗ |
| 56 | 2012 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 338.1K | 55.9K | — | — | — | 3.5K | 1.40M | 0.00% | ↗ |
| 57 | 2012 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 58 | 2011 | Gregory A. Demopulos, M.D. President, Chief Executive Officer, Chairman of the Board of Directors | 600.0K | — | — | — | — | 17.3K | 617.3K | 0.00% | ↗ |
| 59 | 2011 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 600.0K | — | — | — | — | 17.3K | 617.3K | 0.00% | ↗ |
| 60 | 2011 | Gregory A. Demopulos, M.D. President, Chief Executive Officer, Chairman of the Board of Directors and Interim Chief Financial Officer and Treasurer | 600.0K | — | — | — | — | 17.3K | 617.3K | 0.00% | ↗ |
| 61 | 2011 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 310.0K | — | — | — | — | 3.8K | 313.8K | 0.00% | ↗ |
| 62 | 2011 | Marcia S. Kelbon, J.D. Vice President, Patent and General Counsel and Secretary | 310.0K | — | — | — | — | 3.8K | 313.8K | 0.00% | ↗ |
| 63 | 2011 | Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 64 | 2010 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 579.2K | — | — | 1.40M | 91.4K | 23.6K | 2.09M | 66.84% | ↗ |
| 65 | 2010 | Gregory A. Demopulos, M.D. President, Chief Executive Officer, Chairman of the Board of Directors and Interim Chief Financial Officer and Treasurer | 579.2K | — | — | 1.40M | 91.4K | 23.6K | 2.09M | 66.84% | ↗ |
| 66 | 2010 | Gregory A. Demopulos, M.D. President, Chief Executive Officer, Chairman of the Board of Directors | 579.2K | — | — | 1.40M | 91.4K | 23.6K | 2.09M | 66.84% | ↗ |
| 67 | 2010 | Marcia S. Kelbon, J.D., M.S. Vice President, Patent and General Counsel and Secretary | 305.8K | — | — | 377.6K | 47.2K | 3.7K | 734.4K | 51.41% | ↗ |
| 68 | 2010 | Marcia S. Kelbon, J.D. Vice President, Patent and General Counsel and Secretary | 305.8K | — | — | 377.6K | 47.2K | 3.7K | 734.4K | 51.41% | ↗ |
| 69 | 2009 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 475.0K | — | — | — | — | 14.0K | 489.0K | 0.00% | ↗ |
| 70 | 2009 | Gregory A. Demopulos, M.D. President, Chief Executive Officer, Chairman of the Board of Directors | 475.0K | — | — | — | — | 14.0K | 489.0K | 0.00% | ↗ |
| 71 | 2009 | Marcia S. Kelbon, J.D. Vice President, Patent and General Counsel and Secretary | 285.0K | — | — | — | — | 3.7K | 288.7K | 0.00% | ↗ |
| 72 | 2009 | Richard J. Klein Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 73 | 2008 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | 475.0K | — | — | — | — | 25.3K | 500.3K | 0.00% | ↗ |
| 74 | 2008 | Marcia S. Kelbon, J.D. Vice President, Patent and General Counsel and Secretary | 285.0K | — | — | — | — | 3.0K | 288.0K | 0.00% | ↗ |
| 75 | 2008 | Richard J. Klein Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 76 | 2007 | Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors | — | — | — | — | — | — | — | — | ↗ |
| 77 | 2007 | Marcia S. Kelbon, J.D. Vice President, Patent and General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gregory A. Demopulos | Co-Founder, Chairman, Chief Executive Officer & President | 2M | — |
| Peter Cancelmo | Vice President, General Counsel & Corporate Secretary | 665.4K | male |
| David J. Borges | Vice President of Finance, Chief Accounting Officer & Treasurer | 443.8K | male |
| George A. Gaitanaris | Chief Scientific Officer & Vice President of Science | — | — |
| Nadia Dac | Vice President & Chief Commercial Officer | — | female |
| Pamela Pierce Palmer | Co-Founder | — | — |
| Andreas Grauer | Vice President & Chief Medical Officer | — | — |
| Peter W. Williams | Vice President of Human Resources | — | male |
| Catherine A. Melfi | Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems | — | — |
| David W. Ghesquiere | Vice President & Chief Business Development Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OMER
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
